EcoDrugPlus

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSMSIG00000031109
Gene Symbol: FSHR
1 Cross references
214 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSMSIG00000001416
Gene Symbol: FFAR1
1 Cross references
153 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSMSIG00000011857
Gene Symbol: FFAR2
1 Cross references
346 Possible Orthologues:

Fyn-Related Kinase

Ensembl ID : ENSMSIG00000029824
Gene Symbol: FRK
1 Cross references
231 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Pi

Ensembl ID : ENSMSIG00000023250
Gene Symbol: GABRP
1 Cross references
139 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 1

Ensembl ID : ENSMSIG00000023018
Gene Symbol: GABRA1
1 Cross references
217 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 2

Ensembl ID : ENSMSIG00000008755
Gene Symbol: GABRA2
1 Cross references
268 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 4

Ensembl ID : ENSMSIG00000008802
Gene Symbol: GABRA4
1 Cross references
216 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 5

Ensembl ID : ENSMSIG00000015812
Gene Symbol: GABRA5
1 Cross references
277 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 6

Ensembl ID : ENSMSIG00000023032
Gene Symbol: GABRA6
1 Cross references
210 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Beta 1

Ensembl ID : ENSMSIG00000008860
Gene Symbol: GABRB1
1 Cross references
104 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Beta 2

Ensembl ID : ENSMSIG00000023075
Gene Symbol: GABRB2
1 Cross references
287 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).